Cargando…
Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits
Acromegaly is a rare disease characterized by excessive growth hormone secretion, usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some cases, radiation therapy. Current medical therapy consists of treatment with somatostatin analog medications or a growth h...
Autor principal: | Carmichael, John D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269320/ https://www.ncbi.nlm.nih.gov/pubmed/22298946 http://dx.doi.org/10.2147/PPA.S20783 |
Ejemplares similares
-
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
por: Wolin, Edward M., et al.
Publicado: (2016) -
MON-022 Enhancing Patient Care: Co-Creation and Validation of a New and Improved Delivery System for Lanreotide Depot/Autogel and Its Evaluation by US Healthcare Professionals
por: Adelman, Daphne, et al.
Publicado: (2019) -
Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Saif, Muhammad Wasif, et al.
Publicado: (2018) -
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
por: Caplin, Martyn E., et al.
Publicado: (2020) -
Gluteal Subcutaneous Atrophy After Depot Steroid Injection for Allergic Rhinitis
por: Ameratunga, Rohan
Publicado: (2012)